Tom Almey
Chief Operating Officer at Ziphius Vaccines NV
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christian Cardon | M | 56 |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then.
Ghent University
| 10 years |
Olivier Lemaire | M | - |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Annie Vereecken | F | - |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Johan Van Hoof | M | - |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Griet Nuytinck | M | - |
Ziphius Vaccines NV
Ziphius Vaccines NV BiotechnologyHealth Technology Ziphius Vaccines NV is a Belgian biopharmaceutical company that specializes in developing vaccines and therapeutics using its proprietary self-amplifying RNA and carrier technology platforms. The private company is based in Ghent, Belgium and has a portfolio of next-generation vaccine candidates that target infectious diseases and gene supplementation therapies. The company's lead compound, Zip1642, is a COVID-19 vaccine candidate that has undergone preclinical studies. The company was founded in 2019 by Christian Cardon, who has been the CEO since then. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Christian de Wolf | M | - |
Ghent University
| 9 years |
Marion Debruyne | M | 52 |
Ghent University
| 11 years |
Peter Meuris | M | - |
Ghent University
| 1 years |
Paul Demyttenaere | M | 62 |
Ghent University
| 5 years |
Erik Mijten | M | - |
Ghent University
| 4 years |
Davy Ringoot | M | - |
Ghent University
| 5 years |
Lieven Huysse | M | - |
Ghent University
| 3 years |
Ilse Irene Henne | F | 51 |
Ghent University
| 4 years |
Jan Willems | M | 49 |
Ghent University
| 4 years |
Thierry Saegeman | M | - |
Ghent University
| 4 years |
Berg de Bleecker | F | - |
Ghent University
| 5 years |
Rudi Vander Vennet | M | 59 |
Ghent University
| 3 years |
Vincent Macharis | M | 52 |
Ghent University
| 2 years |
Didier Casimiro | M | 57 |
Ghent University
| 4 years |
Jan Holvoet | M | 55 |
Ghent University
| 5 years |
Wim van Criekinge | M | 53 |
Ghent University
| 4 years |
Kristel Verleyen | F | 53 |
Ghent University
| 3 years |
Mario Haneca | M | 52 |
Ghent University
| 4 years |
Vera Goossens | M | - |
Ghent University
| 3 years |
Isabelle Desmeytere | F | 48 |
Ghent University
| 4 years |
Kristoff Jacky Andree Puelinckx | M | 54 |
Ghent University
| 6 years |
Alain Bostoen | M | 54 |
Ghent University
| 3 years |
Luc Vauterin | M | - |
Ghent University
| 3 years |
Koen Hoffman | M | 56 |
Ghent University
| 1 years |
Wim van Camp | M | - |
Ghent University
| 3 years |
Nathalie Sierens | F | - |
Ghent University
| 4 years |
Dany Vandevelde | M | - |
Ghent University
| 5 years |
Davy Vandenheede | M | - |
Ghent University
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 33 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Tom Almey
- Personal Network